Virtual Reality Hypnosis Distraction Utility to Improve Tolerance to Regional Anaesthesia
NCT ID: NCT04024904
Last Updated: 2022-01-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
60 participants
INTERVENTIONAL
2018-07-26
2018-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The second endpoint is to determine if the VRHD increases the patient's satisfaction of their anaesthetic management.
The third endpoint is to study various parameters of use of this specific anaesthetic management: time required for the installation and operation time of the VRHD device; the variation of haemodynamic parameters between the separate groups; pain procedure-related and behavioural pain scale scores between the separate groups.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Virtual Reality Use for Peri-Procedural Analgesia and Anxiolysis
NCT04218396
Pilot Study on the Evaluation of the Effectiveness of a Virtual Reality Device on Anxiety During Procedural Sedation in Traumatology in Emergency Department
NCT04936880
Healthy Volunteer Undergoing Painful Stimuli With and Without Hypnosis and Virtual Reality
NCT04107558
Virtual Reality Hypnosis in Total Knee Arthroplasty Under Spinal Anesthesia
NCT05707234
Virtual Reality in the Management of Painful or Anxiety-provoking Procedures in Emergency Departments
NCT06425835
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Among the non-pharmacologic techniques which may be used to improve the patient's comfort, decrease anxiety and procedure related pain, hypnosis and virtual reality distraction are increasingly used.
In spite of the encouraging scientific and clinical findings, hypnosis for analgesia is not universally used in medical centers. Its widespread use has been limited by factors such as the advanced expertise, time and effort required by clinicians to provide hypnosis, and the commitment required by patients to engage in hypnosis. It is a challenge to make hypnosis a standard part of care in this environment.
Improvements in technologies made virtual reality (VR) distraction a unique practical tool to provide an immersive, multisensory and three-dimensional (3D) environment that creates a sense of presence which enables to modify the perception of reality and to capture a greater degree of attention. Several theories have been proposed to explain how distraction may inhibit or decrease perception of pain by capturing a greater degree of attention. The "virtual reality analgesia" (= analgesia produces by virtual reality) is a product of the attentional distraction. Hoffmann et al. explained that there is a limit to the conscious attentional resources humans have available to process large amounts of incoming information. Conscious attention is required for pain perception. Hoffmann et al. theorize that the more immersive the VR system, the more attention will be drawn into the virtual world, leaving less attention available to process nociceptive signals.
Until now, VR shows an interest in numerous clinical applications (to help treat anxiety disorders, control pain, support physical rehabilitation, and distract patients during wound care) VR technology guides the patient through the same steps used when hypnosis is induced through an interpersonal process. With attentional mechanisms as a common denominator, the attention-captivating qualities of virtual reality and the suggestion inherent in hypnosis, the potential for a synergistic effect between these modalities is significant.
Using a device which combined the advantage of VR technology and hypnosis could probably improve the patient's comfort, decrease his anxiety and procedure related pain.
The first endpoint consist in a significant minimal decrease of 50% of the requirement of IVS delivered to the patient throughout the regional performance, in comparison to the IVS group when using VRHD.
The second endpoint is to determine if VRHD increases patient's satisfaction concerning their anaesthetic management.
The third endpoint is to study various parameters of this specific anesthetic management: time required for the installation and operation time of the VRHD device; variation of haemodynamic parameters; pain procedure-related and behavioural pain scale scores.
Methods Our study is a prospective randomized study. The protocol was approved by the Independent Ethics Committee from Erasmus Hospital.
Written Informed consent was obtained from all participating subjects. Subjects were randomized by the use of a computer-generated random table. Sixty patients scheduled for orthopaedic surgery needing regional anaesthesia are randomized according to the used of VRHD during the regional procedure or before as a complementary premedication.
The patients and the anesthetist in charge of the patient were not blinded but the data collection and statistical analysis were blinded.
Anesthesia management The anesthetic management was standardized for each patient. All subjects were fasting from midnight and premedicated with 0,25-0,5 mg alprazolam per os one hour before the procedure.
During the regional block, the surgical asepsis was respected and the regional block was performed under ultrasound guidance (machine Epic or Philips…). A basic monitoring was installed (EKG (electrocardiogram), NIBP (non-invasive blood pressure), SpO2 (pulse oximetry saturation). A 18 gauge catheter was placed in a vein. To avoid hypoxemia, all patients benefited of a supplemental nasal oxygen (3l/min) if the SpO2 \< 95%.
Intraoperatively, the patient was maintained under sedation or general anesthesia according to the surgical prerequisites.
In the postoperative period, standard care was provided to the patient at the postoperative care unit according the American society of anesthesiologists (ASA) recommendations.
Study protocol In the control group, the patient received the standard pharmacologic intravenous sedation before the regional anaesthesia (2 mg midazolam + 5 µg de sufentanil) without VRHD.
In the study group VRHD 1, the patient received the VHRD technique during the peripheral nerve block and received a pharmacologic intravenous sedation only if the patient's asked for it or if the patient shows some discomfort (behavioural pain scale score \>3).
In the study group VRHD 2, the patient received the VHRD technique a first time before the regional procedure and a second time during the peripheral nerve block. The patient received a pharmacologic intravenous sedation only if the patient's asked for it or if the patient shows some discomfort (behavioural pain scale score \>3).
Virtual reality hypnosis distraction protocol The VHRD technique is the program of OncomfortTM (Oncomfort Inc, Houston, USA). The OncomfortTM device include the hyper vision 3D virtual reality glasses and disposable single-patient-use headphones. The program is an immersive experience focused on inducing relaxation environment and this program exists in durations of 5,15 and 30 minutes.
In the group VHRD 1 and 2, the investigators use the program throughout the regional block. The duration chosen for the VHRD program was 15 or 30 min depending of the time required for the regional procedure.
In the group VHRD 2, the investigators use the program of 5 min for the session occuring before the regional procedure, followed by a 15 or 30 min program during the regional procedure.
Patients were coached by a separate practitioner aside from the regional anesthesiologist performing the regional block.
Study Outcomes The first endpoint consist in a significant minimal decrease of 50% of the requirement of IVS (opioids (µg) and benzodiazepine (mg)) delivered to the patient throughout the regional performance, in comparison to the IVS group when using VRHD.
The second endpoint is to determine if the VRHD increases the patient's satisfaction of their anaesthetic management.
The third endpoint is to study various parameters of this specific anesthetic management: time required for the use and installation of the VRHD device; variation of hemodynamic parameters between the separate groups, pain procedure-related and behavioural pain scale scores between the separate groups;
Statistical Analysis As the first endpoint is to determine if the VRHD decreases the need of pharmacologic intravenous sedation of 50%, the sample size (N=60) is determined by an intention-to-treat test (control group n=20, VRHD 1 n= 20 and VRHD n= 20).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
In the group VHRD 1 and 2 we use the program throughout the regional block. The time choose for the VHRD program is 15 or 30 min depending of the time required for the regional procedure.
In the group VHRD 2, we use the program of 5 min and we applied the device before the regional procedure.
SUPPORTIVE_CARE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
control group
In the control group, the patient received the standard pharmacologic intravenous sedation before the regional anaesthesia (2 mg midazolam + 5 µg de sufentanil) without VRHD (Virtual Reality Hypnosis Distraction).
No interventions assigned to this group
VRHD1
In the study group VRHD (Virtual Reality Hypnosis Distraction) 1, the patient received the VHRD technique during the peripheral nerve block and received a pharmacologic intravenous sedation only if the patient's asked for it or if the patient shows some discomfort (behavioural pain scale score \>3).
OncomfortTM device
The VHRD (Virtual Reality Hypnosis Distraction) technique is the program of OncomfortTM (Oncomfort Inc, Houston, USA). The OncomfortTM device include the hyper vision 3D virtual reality glasses and disposable single-patient-use headphones. The program is an immersive experience focused on inducing relaxation environment and this program exist in 5,15 and 30 minutes
VRHD2
In the study group VRHD (Virtual Reality Hypnosis Distraction) 2, the patient received the VHRD technique for the first time before the regional procedure and a second time during the peripheral nerve block. The patient received a pharmacologic intravenous sedation only if the patient's asked for it or if the patient shows some discomfort (behavioural pain scale score \>3).
OncomfortTM device
The VHRD (Virtual Reality Hypnosis Distraction) technique is the program of OncomfortTM (Oncomfort Inc, Houston, USA). The OncomfortTM device include the hyper vision 3D virtual reality glasses and disposable single-patient-use headphones. The program is an immersive experience focused on inducing relaxation environment and this program exist in 5,15 and 30 minutes
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
OncomfortTM device
The VHRD (Virtual Reality Hypnosis Distraction) technique is the program of OncomfortTM (Oncomfort Inc, Houston, USA). The OncomfortTM device include the hyper vision 3D virtual reality glasses and disposable single-patient-use headphones. The program is an immersive experience focused on inducing relaxation environment and this program exist in 5,15 and 30 minutes
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Erasme University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Van Hecke Delphine
Principal Investigator, attending physician
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
ULB-Erasme Hospital
Brussels, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Hu P, Harmon D, Frizelle H. Patient comfort during regional anesthesia. J Clin Anesth. 2007 Feb;19(1):67-74. doi: 10.1016/j.jclinane.2006.02.016.
Hoffman HG, Seibel EJ, Richards TL, Furness TA, Patterson DR, Sharar SR. Virtual reality helmet display quality influences the magnitude of virtual reality analgesia. J Pain. 2006 Nov;7(11):843-50. doi: 10.1016/j.jpain.2006.04.006.
Pandya PG, Kim TE, Howard SK, Stary E, Leng JC, Hunter OO, Mariano ER. Virtual reality distraction decreases routine intravenous sedation and procedure-related pain during preoperative adductor canal catheter insertion: a retrospective study. Korean J Anesthesiol. 2017 Aug;70(4):439-445. doi: 10.4097/kjae.2017.70.4.439. Epub 2017 Mar 15.
Mulier JP. Perioperative opioids aggravate obstructive breathing in sleep apnea syndrome: mechanisms and alternative anesthesia strategies. Curr Opin Anaesthesiol. 2016 Feb;29(1):129-33. doi: 10.1097/ACO.0000000000000281.
Guenther U, Riedel L, Radtke FM. Patients prone for postoperative delirium: preoperative assessment, perioperative prophylaxis, postoperative treatment. Curr Opin Anaesthesiol. 2016 Jun;29(3):384-90. doi: 10.1097/ACO.0000000000000327.
Wobst AH. Hypnosis and surgery: past, present, and future. Anesth Analg. 2007 May;104(5):1199-208. doi: 10.1213/01.ane.0000260616.49050.6d.
Hauser W, Hagl M, Schmierer A, Hansen E. The Efficacy, Safety and Applications of Medical Hypnosis. Dtsch Arztebl Int. 2016 Apr 29;113(17):289-96. doi: 10.3238/arztebl.2016.0289.
Askay SW, Patterson DR, Sharar SR. VIRTUAL REALITY HYPNOSIS. Contemp Hypn. 2009 Mar;26(1):40-47. doi: 10.1002/ch.371.
Malloy KM, Milling LS. The effectiveness of virtual reality distraction for pain reduction: a systematic review. Clin Psychol Rev. 2010 Dec;30(8):1011-8. doi: 10.1016/j.cpr.2010.07.001. Epub 2010 Jul 13.
Li A, Montano Z, Chen VJ, Gold JI. Virtual reality and pain management: current trends and future directions. Pain Manag. 2011 Mar;1(2):147-157. doi: 10.2217/pmt.10.15.
Tashjian VC, Mosadeghi S, Howard AR, Lopez M, Dupuy T, Reid M, Martinez B, Ahmed S, Dailey F, Robbins K, Rosen B, Fuller G, Danovitch I, IsHak W, Spiegel B. Virtual Reality for Management of Pain in Hospitalized Patients: Results of a Controlled Trial. JMIR Ment Health. 2017 Mar 29;4(1):e9. doi: 10.2196/mental.7387.
Mahrer NE, Gold JI. The use of virtual reality for pain control: a review. Curr Pain Headache Rep. 2009 Apr;13(2):100-9. doi: 10.1007/s11916-009-0019-8.
Carrougher GJ, Hoffman HG, Nakamura D, Lezotte D, Soltani M, Leahy L, Engrav LH, Patterson DR. The effect of virtual reality on pain and range of motion in adults with burn injuries. J Burn Care Res. 2009 Sep-Oct;30(5):785-91. doi: 10.1097/BCR.0b013e3181b485d3.
Furman E, Jasinevicius TR, Bissada NF, Victoroff KZ, Skillicorn R, Buchner M. Virtual reality distraction for pain control during periodontal scaling and root planing procedures. J Am Dent Assoc. 2009 Dec;140(12):1508-16. doi: 10.14219/jada.archive.2009.0102.
Gold JI, Kim SH, Kant AJ, Joseph MH, Rizzo AS. Effectiveness of virtual reality for pediatric pain distraction during i.v. placement. Cyberpsychol Behav. 2006 Apr;9(2):207-12. doi: 10.1089/cpb.2006.9.207.
Hoffman HG, Garcia-Palacios A, Patterson DR, Jensen M, Furness T 3rd, Ammons WF Jr. The effectiveness of virtual reality for dental pain control: a case study. Cyberpsychol Behav. 2001 Aug;4(4):527-35. doi: 10.1089/109493101750527088.
Morris LD, Louw QA, Crous LC. Feasibility and potential effect of a low-cost virtual reality system on reducing pain and anxiety in adult burn injury patients during physiotherapy in a developing country. Burns. 2010 Aug;36(5):659-64. doi: 10.1016/j.burns.2009.09.005. Epub 2009 Dec 21.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B406201836302
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.